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Inflammasomes activate the protease caspase-1,
which cleaves interleukin-1b and interleukin-18 to
generate the mature cytokines and controls their
secretion and a form of inflammatory cell death
called pyroptosis. By generating mice expressing
enzymatically inactive caspase-1C284A, we provide
genetic evidence that caspase-1 protease activity is
required for canonical IL-1 secretion, pyroptosis,
and inflammasome-mediated immunity. In caspase-
1-deficient cells, caspase-8 can be activated at the
inflammasome. Using mice either lacking the pyrop-
tosis effector gasdermin D (GSDMD) or expressing
caspase-1C284A, we found that GSDMD-dependent
pyroptosis prevented caspase-8 activation at the in-
flammasome. In the absence of GSDMD-dependent
pyroptosis, the inflammasome engaged a delayed,
alternative form of lytic cell death that was accompa-
nied by the release of large amounts of mature IL-1
and contributed to host protection. Features of this
cell death modality distinguished it from apoptosis,
suggesting it may represent a distinct form of pro-in-
flammatory regulated necrosis.
INTRODUCTION
Caspases are cysteine aspartic proteases with essential roles in
programmed cell death (Galluzzi et al., 2016). Previously known
as interleukin-1 converting enzyme (ICE), caspase-1 is the proto-
typic inflammatory caspase (Kuida et al., 1995; Thornberry et al.,3846 Cell Reports 21, 3846–3859, December 26, 2017 ª 2017 The A
This is an open access article under the CC BY-NC-ND license (http://1992). By promoting the activation of caspase-1, cytoplasmic
complexes called inflammasomes control the proteolytic matu-
ration of the pro-inflammatory cytokine interleukin (IL)-1b, which
cannot bind the IL-1 receptor in its unprocessed form (Broz and
Dixit, 2016). IL-1b lacks a signal peptide, so it cannot be secreted
by the conventional pathway via the endoplasmic reticulum and
Golgi apparatus. It instead leaves the cell by a poorly understood
unconventional secretory pathway engaged by caspase-1. In-
flammasome activation results in pyroptosis, a specialized
form of lytic, inflammatory cell death defined by its dependence
on inflammatory caspases (Galluzzi et al., 2016). Activation of
caspase-11 (caspase-4 and caspase-5 in humans) by lipopoly-
saccharide (LPS) in the cytoplasm also results in pyroptosis
(Kayagaki et al., 2011). By forming membrane pores, gasdermin
D (GSDMD) executes cell death and IL-1 secretion initiated by in-
flammatory caspases (Ding et al., 2016; He et al., 2015; Kayagaki
et al., 2015; Liu et al., 2016; Sborgi et al., 2016; Shi et al., 2015).
We previously observed that the secretion of IL-1a by myeloid
cells is caspase-1 dependent but insensitive to peptide-based in-
hibitors of caspase-1 (Groß et al., 2012). IL-1a and IL-1b bind the
same receptor (IL1R1), but in contrast to IL-1b, IL-1a is not cleaved
bycaspase-1 and is active in its full-length form. In the presenceof
these inhibitors, cleavage of IL-1b is blocked, but IL-1b is secreted
in its full-length form. Furthermore, when activated independent of
ASC at the NLRC4 or NLRP1 inflammasomes, caspase-1 can
induce pyroptosis without processing IL-1b or itself. Peptide-
based inhibitors are unable to block this cell death (Broz et al.,
2010). Altogether, these results suggested that caspase-1 may
have a non-enzymatic or scaffold function that controls secretion
of IL-1 and pyroptosis. In support of this concept, pro-inflamma-
tory functions that do not strictly rely on enzymatic activity have
also been ascribed to caspase-8 (Kang et al., 2015; Lemmers
et al., 2007; Philip et al., 2016; Suet al., 2005) and the paracaspaseuthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Caspase-1 Protease Activity Is Required for Canonical IL-1 Secretion and Pyroptosis
(A) Unprimed BMDCs derived from B6.129-Casp1+/+ and B6.129-Casp1mlt/mltmice were stimulated for 6 hr with different TLR and Dectin-1 agonists as indicated
or left unstimulated (medium), and IL-6 and TNF secretion were measured in the supernatants by ELISA (data representative of 3 independent experiments).
(legend continued on next page)
Cell Reports 21, 3846–3859, December 26, 2017 3847
MALT1 (Gewieset al., 2014). Furthermore, severalmutations in the
CASP1gene that suppresscaspase-1proteaseactivity havebeen
found in patients with auto-inflammatory conditions that resemble
periodic fever syndromes associated with mutations in NLRP3 or
other inflammasome genes (Luksch et al., 2013).
These indications that caspase-1 may have a pro-inflamma-
tory function independent of its enzymatic activity prompted us
to generate mice deficient for caspase-1 protease activity.
With these Casp1mlt (melted) mice, we demonstrate that in
contrast to biochemical inhibition, genetic inactivation of cas-
pase-1 protease activity impairs not only cleavage of IL-1b but
also canonical IL-1 secretion and pyroptosis at early time points.
Caspase-8 is recruited to the inflammasome and, in caspase-1-
deficient cells, drives late, non-canonical maturation of IL-1b
(Antonopoulos et al., 2015; Pierini et al., 2013). This phenomenon
was also observed in cells expressing enzymatically inactive
caspase-1mlt. Caspase-8 activation at inflammasomes was sup-
pressed by GSDMD-dependent pyroptosis, rather than cas-
pase-1 protease activity per se. Despite efficient caspase-1-
mediated maturation of IL-1b in GSDMD-deficient cells, the
rapid, canonical secretion of IL-1b was impaired. However, in
the absence of GSDMD-dependent pyroptosis, cells engaged
a delayed non-canonical release mechanism that, despite
apoptotic caspase activation, was distinct from apoptosis and
over time allowed for secretion of equivalent amounts of IL-1b.
RESULTS
Generation and Characterization of Casp1mlt Mice
An active site cysteine participates in the proteolytic mechanism
of caspases, including caspase-1 (Thornberry et al., 1992). To
generate mice lacking caspase-1 protease activity, targeting vec-
tors for the introduction of the inactivating C284A mutation into
exon 6 of the murine Casp1 genomic locus were cloned (Figures
S1A andS1B). Themutation changes the genomic sequence from
50-GCATGCCGT-30 to 50-GCAGCGCGT-30, which translates into
the amino acid sequence AAR instead of ACR. The mutation
also generated a HhaI restriction site (GCG^ C) that was used for
screening and genotyping (Figure S1C).
Bonemarrow-deriveddendritic cells (BMDCs) frommicehomo-
zygous for the Casp1mltmutation expressed caspase-1 protein at
normal levels (Figure S1D). Interbreeding of heterozygous mice
produced offspring in the expected Mendelian ratios. Mice
homozygous for the Casp1mlt mutation had growth curves and
fertility indistinguishable from their wild-type littermates (Figures
S1E–S1H). Immunophenotyping analysis was performed on
lymphoidorgansof 8-week-oldCasp1mlt/mltmice andwild-type lit-
termates. Casp1mlt/mltmice and wild-type mice had indistinguish-
able numbers and frequencies of the major immune cell subsets
(Figure S1I; data not shown). Patients withmutations inCASP1 re-
sulting in impaired protease activity display auto-inflammation(B) BMDCs from the indicated mouse strains (B6.129-Casp1mlt/mlt and B6.129
stimulated with agents activating the NLRP3 (nigericin and imiquimod), AIM
flammasomes. IL-1b, pro-IL-1b, and IL-1a (top) and LDH (bottom) were quantifie
(C) Cleavage and secretion of caspase-1 and IL-1b in BMDCs following inflam
Casp1mlt/mlt).
In (A) and (B), mean ± SEM are shown. In (B and (C), data are representative of >
3848 Cell Reports 21, 3846–3859, December 26, 2017(Luksch et al., 2013). However, under specific pathogen-free
(SPF) and specific and opportunistic pathogen-free (SOPF) condi-
tions, mice homozygous for the Casp1mlt mutation were healthy
and did not show obvious signs of spontaneous inflammation or
immunosuppression.
Caspase-1 Protease Activity Is Required for Canonical
IL-1 Secretion, Pyroptosis, and Innate Immunity to
Francisella
BMDCs fromCasp1mlt/mltmice secreted comparable amounts of
tumor necrosis factor (TNF) and IL-6 upon engagement of
various Toll-like receptors and C-type lectin receptors and did
not spontaneously secrete these cytokines (Figure 1A). To genet-
ically test whether caspase-1 protease activity is required for IL-1
secretion and pyroptosis, BMDCs from Casp1mlt/mlt, Casp1/,
and wild-type mice were primed with LPS and then treated for
up to 3 hr with activators of the NLRP3 (nigericin and imiquimod),
AIM2 (poly(dA:dT)), and NLRC4 (Salmonella enterica serovar Ty-
phimurium [S. typhimurium]) inflammasomes. Mature IL-1b, pro-
IL-1b, and IL-1a were quantified in the supernatants by ELISA
(Figure 1B), and cell lysates and supernatants were analyzed
by immunoblotting (Figure 1C) for the presence of the cleaved
and full-length forms of IL-1b and caspase-1. Lactate dehydro-
genase (LDH) activity was measured from supernatants as a
readout for pyroptosis (Figure 1B). Inflammasome activators
induced the secretion of cleaved caspase-1 and IL-1b from cells
expressing wild-type caspase-1. Similar to Casp1/ cells,
Casp1mlt/mlt cells not only failed to cleave IL-1b but also did not
secrete pro-IL-1b or IL-1a and did not undergo pyroptosis at
time points up to 3 hr (Figure 1B). As previously observed (Broz
et al., 2010; Groß et al., 2012), the peptide-based caspase-1 in-
hibitor Ac-YVAD-cmk strongly reduced cleavage of IL-1b and
caspase-1, but cells treated with this inhibitor still secreted the
uncleaved forms of these proteins and underwent pyroptosis
(Figures 1B and 1C). This demonstrates that caspase-1 protease
activity is required for early, canonical IL-1 secretion and pyrop-
tosis and suggests that peptide-based caspase-1 inhibitors fail
to prevent these outcomes of caspase-1 activity.
We targeted the caspase-1 allele in both 129 and C57BL/6
embryonic stem cells (Figures S1A and S1B). Gene targeting is
known to be more efficient in 129 embryonic stem cells, but in-
activating mutations in the Casp11 gene of this strain cannot
be segregated from introduced mutations in Casp1 (Kayagaki
et al., 2011). Because B6.129-Casp1mlt mice were generated
several months before B6-Casp1mlt mice, and because the
appropriate controls (the original B6.129-Casp1/ [ICE/]
mice that harbor the inactivating Casp11 mutation) were readily
available (Kuida et al., 1995), the in vitro studies were first per-
formed in B6.129-Casp1mlt mice (Figure 1) and then confirmed
in B6-Casp1mlt mice (Figures S2A–S2C). We also generated
B6-Casp1/ mice using CRISPR/Cas9 technology to use as-Casp1/11/) were primed with LPS (50 ng/mL for 3 hr) and subsequently
2 (poly(dA:dT)), and NLRC4 (Salmonella enterica serovar Typhimurium) in-
d from cell-free supernatants by ELISA and a colorimetric assay, respectively.
masome activation as in (B) were determined by immunoblotting (B6.129-
10 independent experiments.
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Figure 2. Caspase-1 Protease Activity Is Required for Innate Immunity to Francisella
(A–D) Bacterial loads in spleens (A and C) and livers (B and D) of mice infected with Francisella novicida for 48 hr were determined by plating serial dilutions of
organ homogenates on selectivemedium plates. In (C) and (D), the wild-type group consists of littermates of B6.129-Casp1mlt/mltmice; B6.129-Casp1/ animals
were matched by age and sex and were bred in the same isolator. The Mann-Whitney test was used for statistical analysis (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001). (A and B) Spleen: Casp1/, p = 0.0317; Casp1mlt/mlt, p = 0.0175; liver: Casp1/, p = 0.0303; Casp1mlt/mlt, p = 0.00012; B6-Casp1/ and
littermate B6-Casp1+/+: n = 5; B6-Casp1mlt/mlt and littermate B6-Casp1+/+: n = 7. (C and D) Spleen:Casp1mlt/mlt, p < 0.0001; liver:Casp1mlt/mlt, p = 0.0076; B6.129-
Casp1mlt/mlt and littermate B6.129-Casp1+/+: n = 9 and n = 10, respectively; B6.129-Casp1/: n = 4.controls for B6-Casp1mlt mice. Previous studies have estab-
lished a requirement for caspase-1 activation via the DNA-
sensing AIM2 inflammasome for innate immunity against the
facultative intracellular pathogen Francisella tularensis subspe-
cies novicida (F. novicida) (Fernandes-Alnemri et al., 2010).
Similar to Casp1/ mice, Casp1mlt/mlt mice from both the
C57BL/6 and the 129 backgrounds were susceptible to Franci-
sella, displaying an elevated bacterial load in the spleen and liver
upon infection (Figure 2). These results demonstrate that cas-
pase-1 protease activity is required for protection against
Francisella.
Caspase Inhibitors Vary in Their Ability to Prevent
GSDMD Cleavage and Pyroptosis
Because genetic inactivation of caspase-1 protease activity pre-
vented both IL-1 secretion and pyroptosis at early time points,
we examined why peptide-based inhibitors of caspase-1 have
a qualitatively different effect. The effect of VX-765, a new pep-tidomimetic inhibitor of caspase-1 (Wannamaker et al., 2007),
on secretion of cleaved IL-1b was comparable to that of Ac-
YVAD-cmk (Figure 3A). In contrast to Ac-YVAD-cmk, VX-765
prevented pyroptosis (Figure 3A). GSDMD was identified as a
cleavage target of caspase-1 and caspase-11 (Agard et al.,
2010) required for pyroptosis and IL-1 secretion (He et al.,
2015; Kayagaki et al., 2015; Shi et al., 2015). The differential abil-
ity of VX-765 and Ac-YVAD-cmk to inhibit pyroptosis was re-
flected in the prevention of GSDMD cleavage by VX-765, but
not by Ac-YVAD-cmk (Figure 3B). The pan-caspase inhibitor
Z-VAD-fmk preventedGSDMDcleavage only at toxic concentra-
tions in which it alone caused release of cytoplasmic proteins,
presumably by inducing necroptosis (Figures 3B and S3).
Consistent with the inability of Casp1mlt/mlt cells to pyroptose
at early time points, GSDMD cleavage was not observed in
Casp1mlt/mlt cells after treatment with inflammasome activators
(Figure 3C). The release of the uncleaved pro-form of IL-1b in
the presence of caspase-1 inhibitors at early time points wasCell Reports 21, 3846–3859, December 26, 2017 3849
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Figure 3. Caspase Inhibitors Vary in Their Ability to Prevent GSDMD Cleavage and Pyroptosis
(A) BMDCs were pretreated with the indicated doses of the caspase-1 inhibitors Ac-YVAD-cmk and VX-765 for 30 min and stimulated with 5 mM nigericin for
45 min, and secretion of IL-1b and release of LDH into the supernatant were measured (mean ± SEM are shown).
(B) BMDCs were pretreated with caspase inhibitors as indicated and stimulated with nigericin. Caspase-1 and GSDMD cleavage were assessed by immunoblot
analysis.
(C) BMDCs from wild-type, B6.129-Casp1/, and B6.129-Casp1mlt/mlt mice were stimulated with nigericin, and GSDMD cleavage was analyzed in cytoplasmic
fractions by immunoblotting.
(D) BMDCs from the indicated mouse strains (B6.129-Casp1mlt/mlt) were pretreated with caspase inhibitor Z-VAD-fmk (20 mM) or Ac-YVAD-cmk (30 mM) and
stimulated with nigericin for 1.5 hr. Secretion of the cleaved and uncleaved forms of IL-1b was assessed by immunoblot analysis from cell-free cell culture
supernatants.
(A–C) Data representative ofR3 independent experiments.GSDMD dependent (Figure 3D). Altogether, these results sug-
gest that VX-765 is a superior caspase-1 inhibitor and that resid-
ual cleavage of GSDMD in the presence of Ac-YVAD-cmk is suf-
ficient for pyroptosis and IL-1 release.
Caspase-1mlt Accumulates at the Inflammasome
A common feature of inflammasome activation is ASC polymer-
ization and formation of a detergent-insoluble speck (Fernandes-
Alnemri et al., 2007). To determine whether protease activity
of caspase-1 influences its ability to be recruited to the ASC
speck, wild-type and Casp1mlt/mlt BMDCs were treated with in-
flammasome activators, and inflammasome formation was
monitored by confocal and super-resolution immunofluores-
cence microscopy of fixed cells and immunoblotting of the
detergent-insoluble fraction of cells. Caspase-1mlt strongly
accumulated at the inflammasome or speck (Figures 4A–4C
and S4A), presumably because unlike wild-type caspase-1, it
fails to liberate itself by auto-cleavage. Treatment with the cas-
pase-1 inhibitor Ac-YVAD-cmk also caused caspase-1 to accu-
mulate at the inflammasome (Figure 4A).
Our results suggested that caspase-1proteaseactivity iscritical
for canonical IL-1 secretion and pyroptosis but do not rule out that
caspase-1mayhave functions that donot strictly require protease
activity. The accumulation of caspase-1mlt in the insoluble fraction3850 Cell Reports 21, 3846–3859, December 26, 2017presented a means to enrich factors that stably interact with
caspase-1 at the inflammasome yet avoid potential confounding
effects of pyroptosis. Cells of genotypes incapable of caspase-
1-dependent pyroptosiswere treatedwith nigericin, and the insol-
uble fraction (Figure 4C) was prepared in quadruplicate and
analyzed by label-free mass spectrometry. As expected, ASC
was consistently enriched in the insoluble fraction of Casp1mlt/mlt
cells relative to Nlrp3/ cells (Figure 4D). Caspase-1 was also
strongly enriched in the insoluble fraction ofCasp1mlt cells relative
to Nlrp3/ and Casp1/ cells. However, more than 1,000 other
proteins were detected in this cellular fraction, and none of them
were reproducibly enriched in an NLRP3- or caspase-1-depen-
dent manner. The strong enrichment of caspase-1 and ASC in
this fraction indicates that they are the most abundant compo-
nents of the inflammasome, but it is clear that better purification
techniqueswill be required to identify potential regulatory compo-
nents with lower abundance. For example, while caspase-8 can
be found in ASC specks (Figures 5A and 5B) (Sagulenko et al.,
2013), it was not detected by mass spectrometry.
Enhanced Activation of Caspase-8 and Non-canonical
IL-1b Processing in Cells Expressing Caspase-1mlt
Although ASC-containing inflammasomes can recruit caspase-
8, the initiator caspase of the extrinsic apoptosis pathway,
A B
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Figure 4. Caspase-1mlt Accumulates at the Inflammasome
(A) BMDCs fromB6.129-Casp1mlt/mlt or wild-typemice on culture slides were pretreated with 20 mMAc-YVAD-cmkwhere indicated and subsequently stimulated
with nigericin. Cells were fixed with paraformaldehyde, stained by immunofluorescence for caspase-1 (green) and ASC (magenta), and analyzed by confocal
microscopy. DAPI (blue) localizes with the nuclei. Scale bar represents 20 mm (data representative of >5 independent experiments).
(B) BMDCs fromB6.129-Casp1mlt/mlt or wild-typemice on culture slides, the latter pretreatedwith 20 mMAc-YVAD-cmk, were stimulated with nigericin, fixed, and
stained by immunofluorescence for caspase-1 (green) and ASC (magenta). ASC specks were visualized at high resolution by STED imaging.
(C) BMDCs of the indicated genotypes (B6.129-Casp1/ and B6.129-Casp1mlt/mlt) were primed with LPS and subsequently stimulated with nigericin. An IGEPAL
CA-630-insoluble fraction was isolated by centrifugation, and cell lysates, insoluble fractions, and soluble fractions were analyzed for the presence of ASC,
caspase-1, and vimentin as fractionation control by immunoblotting. c.l., cell lysate; i.f., insoluble fraction.
(D) Four replicates each of BMDCs from B6.129-Casp1mlt/mlt, Nlrp3/, and B6.129-Casp1/ were stimulated and prepared as in (C), and insoluble fraction
samples were analyzed bymass spectrometry. The relative enrichment of proteins detected in B6.129-Casp1mlt/mlt overNlrp3/ or B6.129-Casp1/ samples is
plotted against the inverse relative SD (RSD) within the B6.129-Casp1mlt/mlt quadruplet (mean/SD).
(C and D) Data representative of 2 independent experiments with n = 4 replicates per genotype.pyroptosis is the predominant form of cell death in response to
inflammasome activators when caspase-1 is present. However,
in the absence of caspase-1, caspase-8 is activated at the in-
flammasome and has been reported to be associated with fea-
tures of apoptosis (Antonopoulos et al., 2015; Pierini et al.,2012; Sagulenko et al., 2013). One possible explanation for the
activation of caspase-8 is that in the absence of caspase-1,
naked ASC specks can more efficiently recruit caspase-8. How-
ever, recruitment of caspase-8 to ASC specks was similar in
Casp1mlt/mlt cells and Casp1/ cells (Figures 5A, S4B, andCell Reports 21, 3846–3859, December 26, 2017 3851
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S4C). This also suggests that caspase-1 and caspase-8 do not
compete for the same binding sites at the inflammasome.
Consistent with this idea and previous biochemical and struc-
tural studies (Fu et al., 2016; Vajjhala et al., 2015), caspase-1
and caspase-8 occupied distinct areas in inflammasomes
imaged by super-resolution microscopy (Figure S4D). Although
most ASC specks in all genotypes displayed some caspase-8
positivity, caspase-8 recruitment was markedly enhanced in
the absence of caspase-1 activity (Figures 5A, S4B, and S4C).
However, immunoblotting analysis revealed that only a small
fraction of the cellular pool of caspase-8 was recruited to the in-
flammasome (Figure 5B). This is consistent with previous obser-
vations (Sagulenko et al., 2013) and could explain whywe did not
detect caspase-8 bymass spectrometry. Similarly, the caspase-
8 interaction partners cFLIP, FADD, and RIPK1 were also de-
tected in the specks, together with caspase-8, when caspase-
1 was absent (Figures S5A and S5B).
Cleavage of caspase-8 to generate the active p18 fragment
was also similar between Casp1/ and Casp1mlt/mlt cells (Fig-
ures 5B and 5C). This phenomenon required formation of the in-
flammasome platform, because cleavage of caspase-8 was not
observed in the absence of ASC (Pycard/) (Figure 5B), as re-
ported previously (Antonopoulos et al., 2015; Pierini et al.,
2012; Sagulenko et al., 2013). Caspase-8 cleavage was readily
detected in Casp1/ and Casp1mlt/mlt cells after 3 hr of inflam-
masome activation but could also be observed as early as 1 hr
after stimulation with nigericin (Figure 5C). Although caspase-8
is recruited to the ASC speck in wild-type cells (Figures 5A,
S4B, and S4C), cleavage of caspase-8 was not observed in
wild-type cells treated with several inflammasome activators
for up to 24 hr (Figure S5C).
Caspase-8 can directly cleave IL-1b to generate the mature
form (Maelfait et al., 2008), and caspase-8 activation at the
ASC speck in caspase-1-deficient cells can lead to non-canon-
ical (caspase-1-independent) IL-1b maturation after prolonged
activation of the inflammasome (Antonopoulos et al., 2013; Pier-
ini et al., 2013). Wild-type cells rapidly secreted cleaved IL-1b as
expected (Figures 5C and 5D). The non-canonical cleavage of
IL-1b in Casp1/ and Casp1mlt/mlt cells correlated with activa-
tion of caspase-8 and was inhibited by the pan-caspase inhibitor
Z-VAD-fmk and the caspase-8 inhibitor IETD-fmk (Figures 5C,
5D, and S5D). Casp1/ and Casp1mlt/mlt cells, but not ASC-
deficient cells (Figure S5C), also secreted mature IL-1b after
prolonged stimulation with inflammasome activators, which
suggests that these cells engage a non-canonical but ASC-
dependent secretion pathway that does not rely on caspase-1Figure 5. Enhanced Activation of Caspase-8 in Cells Expressing Casp
(A) BMDCs of the indicated genotypes (B6.129-Casp1mlt/mlt) on culture slides w
caspase-1 (cyan), caspase-8 (yellow), and ASC (magenta), and then confocal ima
20 mm (data representative of >5 independent experiments).
(B) BMDCs from differentCasp1 genotypes as indicated (B6-Casp1mlt/mlt) and ASC
IGEPAL CA-630-insoluble fractions following LPS priming and inflammasome ac
periments). c.l., cell lysate; s.f., soluble fraction; i.f., insoluble fraction; h.e., high
(C) Cleavage and secretion of IL-1b and caspase-1 and generation of caspase-8
BMDCs from the indicated genotypes (B6-Casp1mlt/mlt) with nigericin, imiquimod
(MOI 20).
(D) Secretion of mature IL-1b in conditions as in (C) was measured by ELISA (me
In (C) and (D), data are representative of 5 independent experiments.protease activity (Figures 5D and S5C). However, wild-type cells
secreted substantially more IL-1b than did Casp1/ and
Casp1mlt/mlt cells (Figures 5C and 5D), indicating that the effi-
ciency of either IL-1b processing or IL-1b release is reduced in
the absence of caspase-1 activity.
Inflammasome-Induced Lytic Cell Death and IL-1
Release in GSDMD-Deficient Cells
Our data suggest that enhanced inflammasome-induced cas-
pase-8 activation in the absence of caspase-1 was not merely
a consequence of increased availability of potential binding sites
on ASC and instead implied that the absence of caspase-1 pro-
tease activity or a consequence thereof permits caspase-8 acti-
vation at the inflammasome. Thus, we asked how caspase-1
protease activity suppresses caspase-8 activation at the inflam-
masome. Aside from itself, IL-1b, and GSDMD, caspase-1 has
several other substrates that could potentially account for this
phenomenon (Agard et al., 2010; Denes et al., 2012). As ex-
pected, short-term (%3 hr) stimulation with inflammasome acti-
vators triggered release of cleaved IL-1b and LDH fromwild-type
cells, but not from cells lacking GSDMD, caspase-1, or caspase-
1 protease activity (Figures 6A and 6B). Similar to Casp1/ and
Casp1mlt/mlt cells and in contrast towild-type cells, GSDMD-defi-
cient cells displayed robust caspase-8 activation (Figure 6A).
This indicates that caspase-1 activity results in the suppression
of caspase-8 activation by inducing GSDMD-dependent pyrop-
tosis. Gradual loss of intracellular caspase-8 was observed dur-
ing GSDMD-dependent pyroptosis, and it is possible that this
contributes to the reduced activation of caspase-8 in wild-type
cells (Figures 5B and S5D). However, inhibition of pyroptotic lysis
in wild-type cells by addition of glycine (Brennan and Cookson,
2000) did not restore caspase-8 activation (Figures S5D and
S5E), suggesting that lysis is not the primary reason for suppres-
sion of inflammasome-induced caspase-8 activity in wild-type
cells. Both caspase-1 and caspase-8 are activated in GSDMD-
deficient cells, and this coincided with stronger intracellular
cleavage of IL-1b (generating the bioactive p17 subunit) than
was observed in cells lacking caspase-1 protease activity. Other
caspase-dependent (Figure S5D) IL-1b cleavage and degrada-
tion products were observed in cells lacking caspase-1 protease
activity, but these were not released (Figures 5C and 6A). IL-1b
p17 was initially retained in cells; its delayed but robust
GSDMD-independent release coincided with release of the lytic
cell death marker LDH (Figures 6A and 6B) and the alarmin IL-1a
(Figure S6A). The late LDH release was comparable in GSDMD-
deficient cells, in which both caspase-1 and caspase-8 arease-1mlt
ere stimulated with nigericin, fixed, and stained by immunofluorescence for
ging was performed. DAPI (blue) localizes with the nuclei. Scale bar represents
-deficient cells (Pycard/) were investigated for recruitment of caspase-8 into
tivation by nigericin (for 0.5 or 8 hr) (data representative of 2 independent ex-
exposure.
p18 were monitored by immunoblot analysis 1, 3, and 9 hr after stimulation of
(70 mM), poly(dA:dT) (1 mg/mL), and Salmonella enterica serovar Typhimurium
an ± SEM are shown).
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Table 1. Summary of the Molecular and Cellular Features of Secondary Pyroptosis in Comparison to Other Forms of Cell Death
Apoptosis Necroptosis Pyroptosis Secondary Pyroptosis Source
ASC dependent   + + 1, 2, 3, this manuscript
Caspase-1 dependent   +  1, 2, 3, this manuscript
GSDMD dependent   +  This manuscript
Cell swelling  + + + This manuscript
Blebbing, formation of apoptotic bodies +    This manuscript
Loss of membrane integrity (i.e., propidium
iodide, DRAQ7 uptake)
 + + + 1, 2, 3, this manuscript
Cell lysis, LDH release  + + + 1, 3, this manuscript
Phosphatidylserine exposure ++ + + + 1, this manuscript
Pore formation  + MLKL + GSDMD NDa ND
Caspase-8 activation +   + 1, 2, 3, this manuscript
Caspase-3 activation +   + 1, 2, 3, this manuscript
PARP cleavage ++  + ++ This manuscript
DNA fragmentation + + (+)b + 1, 2
Nuclear condensation + + + + 1, this manuscript
NEC1 sensitivity  +   This manuscript
Sensitive to caspase inhibitors +++ ()c ± + This manuscript
IL-1 release   ++ ++ 3, this manuscript
The source column refers to the description of cell death induced by the inflammasome but independent of caspase-1. Previous reports characterized
this cell death as apoptosis: (1) Pierini et al. (2012), (2) Sagulenko et al. (2013), and (3) Antonopoulos et al. (2015).
aThe effector of secondary pyroptosis remains to be investigated but is potentially another gasdermin.
bNLRC4 activation by bacteria was observed to be accompanied by DNA fragmentation and laddering in wild-type cells (Miao et al., 2011). In contrast,
(1) Pierini et al. (2012) and (2) Sagulenko et al. (2013) did not observe this phenomenon after stimulation of the AIM2 or NLRP3 inflammasome, respec-
tively, in wild-type or ASC-deficient cells but instead only observed it in the absence caspase-1.
cNecroptosis occurs when caspase-8 is inhibited.activated at the inflammasome, and in cells lacking caspase-1
protease activity, which suggests that this delayed, inflamma-
some-induced, LDH-releasing death in GSDMD-deficient cells
is not driven by other potential substrates of caspase-1 (Fig-
ure 6B). In contrast, while the amount of IL-1b released from
GSDMD-deficient cells eventually reached wild-type levels, cells
lacking caspase-1 protease activity secreted less mature IL-1b
even at late time points (Figures 6A and 6B), which is consistent
with inefficient processing of IL-1b to the mature p17 form by
caspase-8 (Maelfait et al., 2008) and the observation of addi-
tional IL-1b cleavage and degradation bands in cells lacking cas-
pase-1 activity. Altogether, these results indicate that ineffective
proteolytic processing of IL-1b accounts for reduced levels of
mature IL-1b in the supernatant of cells lacking caspase-1 activ-Figure 6. GSDMD-Dependent Pyroptosis Suppresses Caspase-8 Activ
(A) BMDCs of wild-type,Gsdmd/, B6-Casp1/, and B6-Casp1mlt/mltmice were
secretion of IL-1b after inflammasome activation by nigericin or poly(dA:dT) for 3
(B) Measurement of released IL-1b by ELISA and LDH by an enzymatic assay fro
(C) Following infection with F. novicida for 48 hr, bacterial loads in spleens (left) and
by plating serial dilutions of organ homogenates on selective medium plates. T
***p < 0.001, ****p < 0.0001). Spleen: Gsdmd/ versus wild-type, p = 0.0017
Casp1/, p < 0.0001; liver: Gsdmd/ versus wild-type, p = 0.0004; Gsdmd
p < 0.0001; wild-type, B6.129-Casp1/, and Gsdmd/: n = 16.
(D) BMDCs from B6.129-Casp1mlt/mlt mice on chambered coverslips were stimula
over time by differential interference contrast (DIC) and fluorescence microscopy
(E) BMDCs of wild-type, B6.129-Casp1/, and Pycard/mice were pretreated w
(30 mM) and subsequently stimulated with nigericin. Lytic cell death was quantifie
In (A) and (B), data are representative of 2 independent experiments.ity, while the alternative secretionmechanism engaged by the in-
flammasome in the absence of GSDMD cleavage by caspase-1
leads to the robust release of IL-1. The preservation of a certain
degree of IL-1 processing and secretion in GSDMD-deficient
cells would suggest that defects in caspase-1 activity should
have a stronger effect than GSDMD deficiency in vivo.
GSDMD-deficient mice displayed a less severe phenotype
than did caspase-1 knockout mice during F. novicida infection
(Figure 6C).
We next investigated the mechanism of inflammasome-
induced lytic cell death that was observed in cells incapable of
GSDMD-dependent pyroptosis (Table 1). Previous studies
have shown that caspase-8 activation in caspase-1-deficient
cells treated with inflammasome activators correlates withation
analyzed by immunoblot for caspase-8 processing, as well as maturation and
, 9, or 18 hr.
m samples in (A) (mean ± SEM are shown).
livers (right) of wild-type,Gsdmd/, and B6.129-Casp1micewere determined
he Mann-Whitney test was used for statistical analysis (*p < 0.05, **p < 0.01,
; Gsdmd/ versus B6.129-Casp1/, p = 0.0014; wild-type versus B6.129-
/ versus B6.129-Casp1/, p = 0.0189; wild-type versus B6.129-Casp1/,
ted with nigericin or 10 mM raptinal and monitored for morphological changes
. Loss of membrane integrity was indicated by DRAQ7 (red) staining of DNA.
ith the caspase inhibitors Z-VAD-fmk (20 mM), IETD-fmk (30 mM), or DEVD-fmk
d by LDH release as measured by an enzymatic assay after 4, 8, 12, and 16 hr.
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features of apoptosis such as activation of executioner cas-
pases, nuclear condensation, DNA fragmentation, and phospha-
tidylserine exposure (Antonopoulos et al., 2015; Pierini et al.,
2012; Puri et al., 2012; Sagulenko et al., 2013). Inflammasome
activators triggered caspase-3 cleavage, PARP cleavage, and
phosphatidylserine exposure in cells incapable of GSDMD-
dependent pyroptosis (Figures 6A, S6B, and S6C; Table 1). As
expected, inducers of apoptosis such as raptinal and doxoru-
bicin triggered blebbing before loss of membrane integrity (Fig-
ures 6D andS6D). In contrast, cells incapable of GSDMD-depen-
dent pyroptosis lost membrane integrity without prior blebbing
upon treatment with inflammasome activators (Figure 6D). The
loss of membrane integrity and the release of LDH by cells inca-
pable of GSDMD-dependent pyroptosis indicate the existence
of an alternative lytic cell death mechanism triggered by the in-
flammasome. The lack of blebbing suggests that this cell death
pathway is not simply necrosis secondary to apoptosis, though
the deathmodalities may employ the same upstreammachinery.
Several observations suggest that this lytic, inflammatory cell
death pathway is not necroptosis: the robust activation of cas-
pase-8 and caspase-3 (Figure 6A), the concomitant degradation
of RIPK1 (Figure S5A), and the insensitivity to necrostatin-1 (Fig-
ure S6E). ASC deficiency markedly reduced lytic death at early
and late phases, suggesting that the inflammasome platform is
important not only for pyroptosis but also for this alternative lytic
death pathway (Figures 6E and S6C). A bioluminescence assay
revealed strong activation of caspases in cells lacking cas-
pase-1 protease activity (Figure S6F). Furthermore, the pan-cas-
pase inhibitor Z-VAD-fmk substantially (and to a lesser extent,
the caspase-8 and caspase-3 inhibitors IETD-fmk and DEVD-
fmk, respectively) reduced lytic death in cells lacking caspase-1
protease activity, suggesting that this form of cell death is driven
by caspase activity (Figure 6E). The inability of these inhibitors to
completely prevent lytic cell death is similar to the failure of pep-
tide-based caspase-1 inhibitors to block GSDMD-dependent
pyroptosis (Figure 3). Collectively, our data indicate that cas-
pase-1 protease activity is required for pyroptosis and secretion
ofmature IL-1 at early time points after inflammasome activation.
However, this study also demonstrates that in the absence of
caspase-1 activity, the inflammasome activates caspase-8 and
other caspases to trigger a GSDMD-independent secondary py-
roptosis pathway as an alternative means to releasemature IL-1.
DISCUSSION
We have generated and analyzedmice expressing enzymatically
inactive caspase-1C284A, which we have named Casp1mlt. In
contrast to the previous observation that biochemical inhibition
of caspase-1 by peptide-based inhibitors selectively blocks
IL-1b cleavage but does not prevent pyroptosis or IL-1 secretion
(Broz et al., 2010; Cullen et al., 2015; Groß et al., 2012), genetic
inactivation of caspase-1 protease activity prevented not only
IL-1b cleavage but also canonical IL-1 secretion and pyroptosis
at early time points after inflammasome activation. The inability
of Ac-YVAD-cmk to block cleavage of the pyroptotic effector
GSDMD explains this discrepancy. The inhibition of both arms
of caspase-1 inflammatory activity—IL-1 secretion and pyropto-
sis—was recapitulated by VX-765, a second-generation pepti-3856 Cell Reports 21, 3846–3859, December 26, 2017domimetic inhibitor of caspase-1. Peptide-based caspase inhib-
itors can block apoptosis and have therefore been key tools in
apoptosis research. In contrast, our results speak to the limited
utility of such inhibitors in studying pyroptosis, because residual
caspase activity and gasdermin processing are sufficient for lytic
cell death.
Additional facets of the interplay between caspase-1 and cas-
pase-8 at the inflammasome were revealed by analysis of
Casp1mlt mice. Although caspase-1mlt strongly accumulated at
the inflammasome, inflammasomes containing caspase-1mlt re-
cruited and activated caspase-8 as effectively as naked, cas-
pase-1-deficient inflammasomes. This suggests that caspase-
1, which is recruited to ASC by a homotypic caspase recruitment
domain (CARD) interaction, does not compete with caspase-8
for the same binding sites on ASC in native myeloid cell inflam-
masomes. Structural studies and inflammasome reconstitution
experiments in HEK293T cells showed that caspase-8 is re-
cruited via its tandem DED domains to the PYD domain of ASC
(Fu et al., 2016; Pierini et al., 2012; Sagulenko et al., 2013; Vajj-
hala et al., 2015). Mass spectrometry analysis of the inflamma-
some-enriched insoluble fraction demonstrated that ASC and
caspase-1 were the most enriched proteins in this fraction.
Detection of caspase-8 and other, less abundant components
of the inflammasome will likely require improved enrichment
methods.
Our data suggested that caspase-1 protease activity or its
sequelae suppress caspase-8 activation at the inflammasome.
Several substrates of caspase-1 have been identified (Agard
et al., 2010; Denes et al., 2012), but deficiency of GSDMD alone
allowed for simultaneous activation of caspase-8 and caspase-1
at the inflammasome. These findings imply that GSDMD-depen-
dent pyroptosis, rather than caspase-1 activity per se, precludes
inflammasome-induced activation of caspase-8. Further studies
will be necessary to mechanistically explain how pyroptosis in-
hibits caspase-8 activation at the inflammasome. Our finding
that inhibiting pyroptotic lysis does not restore caspase-8 activa-
tion in wild-type cells suggests an active signaling eventmight be
involved.
In cells lacking caspase-1, activation of caspase-8 at the in-
flammasome has been implicated in the non-canonical matura-
tion of IL-1b (Antonopoulos et al., 2015; Pierini et al., 2013). We
observed the same phenomenon in cells specifically lacking cas-
pase-1 protease activity. In line with previous in vitro cleavage
assays (Maelfait et al., 2008), caspase-8-associated non-canon-
ical processing of IL-1b in cells was less effective than caspase-
1-mediated processing. In contrast to the rapid release of
mature IL-1b from wild-type cells, IL-1b secretion from cells
lacking caspase-1 protease activity was delayed. Despite this
delay, GSDMD-deficient cells (in which caspase-1 is active) effi-
ciently cleaved IL-1b and eventually released amounts of IL-1b
equivalent to those released by wild-type cells. Thus, the non-
canonical IL-1 release mechanism associated with caspase-8
activation and lytic cell death eventually compensated for the
lack of rapid, caspase-1-driven, GSDMD-dependent release
mechanisms. These findings also suggest that the ability of
caspase-8 to contribute to IL-1-dependent inflammation may
be limited by its inefficient cleavage of IL-1b. This is supported
by our observation that intact caspase-1-mediated IL-1b
processing in GSDMD-deficient mice correlates with enhanced
protection of these mice relative to caspase-1-deficient mice
during Francisella infection. Nonetheless, a role for caspase-8-
driven non-canonical maturation and release of IL-1 in protection
against infection is supported by previous in vivo studies
showing that ASC-deficient mice (which lack both canonical
and non-canonical IL-1 maturation and release pathways) are
more susceptible to bacterial infection than caspase-1/11-defi-
cientmice (Pierini et al., 2013). Collectively, these results suggest
that alternative IL-1 maturation and release pathways contribute
to immunity in vivo.
GSDMD-deficient cells are protected from caspase-11-driven
cell death in response to intracellular LPS, even at late time points
(Kayagaki et al., 2015; Shi et al., 2015). In contrast, we find that
GSDMD-deficient cells treated with canonical activators that
cause formation of an ASC-containing inflammasome are initially
protected from cell death but lyse and release IL-1 after 8 hr.
Though one possible explanation is that other caspase-1 cleav-
age targets mediate this alternative death pathway in GSDMD-
deficient cells, our finding that delayed lytic death after inflamma-
some activation occurred with a similar strength and kinetics in
GSDMD-deficient cells as in cells lacking caspase-1 protease ac-
tivity demonstrates that caspase-1 protease activity is dispens-
able for this alternative lytic cell death modality. These results
also raise the question of whether the formation of an ASC-con-
taining inflammasome is a commitment to cell death. This issue
may be worth considering in HIV infection, in which there is inter-
est in using caspase-1 inhibitors to prevent pathogenic depletion
of unproductively infected CD4+ T cells (Doitsh et al., 2014). The
inflammasome can serve as a platform for caspase-8 activation
in CD4+ T cells, so even effective caspase-1 inhibitors such as
VX-765mayonly delayHIV-induced death of these cells by divert-
ing them to the slower alternative death pathway associated with
caspase-8 activation (Martin et al., 2016). Therefore, in conditions
such as HIV infection, cryopyrin-associated periodic syndromes,
and sepsis, in which pyroptosis is implicated in pathogenic
inflammation or cell depletion (Brydges et al., 2013; Kayagaki
et al., 2011), it may bemore effective to develop strategies to pre-
vent formation of the inflammasome.
The inflammasome-induced delayed lytic cell death observed
in cells incapable of GSDMD-dependent pyroptosis was driven
by activation of caspase-8. Caspase-8 initiates the extrinsic
apoptosis pathway by cleaving executioner caspases, which in
turn degrade cellular proteins and kill the cell. Apoptosis is
defined as an immunologically silent form of cell death; it pre-
serves plasma membrane integrity and therefore does not
release inflammatory cytokines or alarmins. Regulated necrosis
pathways—including necroptosis, pyroptosis, and several other
recently discovered cell deathmodalities—cause cell lysis but, in
contrast to passive necrosis, are genetically controlled. Previous
studies have classified inflammasome-induced cell death in cas-
pase-1-deficient cells as apoptosis based on the observation of
caspase-3 cleavage, phosphatidylserine exposure, nuclear
condensation, and DNA degradation (Antonopoulos et al.,
2015; Pierini et al., 2012; Puri et al., 2012; Sagulenko et al.,
2013). Yet in contrast to apoptosis, inflammasome-induced
cell death in cells lacking caspase-1 protease activity was lytic
and released large amounts of IL-1. Its requirement for upstreaminflammasome components and its sensitivity to caspase inhibi-
tion demonstrate regulation. However, the lack of apoptotic
blebbing before lysis suggests that this necrotic pathway was
not simply secondary to apoptosis and therefore may represent
a distinct form of regulated necrosis. On the basis of its specific
features and its delay relative to canonical, caspase-1-depen-
dent pyroptosis (Table 1), this lytic, inflammasome-dependent
cell death might be considered a non-canonical or secondary
form of pyroptosis. This adds another form of cell death to those
already linked to caspase-8, raising the question how amolecule
like caspase-8 has evolved such roles in diverse forms of cell
death, including apoptosis, necroptosis, and secondary pyrop-
tosis. This will be an intriguing topic for further study. The
pore-forming gasdermin family member DFNA5 (Ding et al.,
2016) was identified as a substrate of caspase-3 that executes
secondary necrosis (Rogers et al., 2017) and lytic cell death in
response to chemotherapeutics (Wang et al., 2017). DFNA5 is
cleaved in parallel to other caspase substrates, so cell-type-spe-
cific differences in the balance of DNFA5 and executioners of
apoptosis may govern the relative kinetics of classical apoptosis
and regulated necrosis driven by apoptotic caspases. Cleavage
of DFNA5 by caspase-3 may represent a mechanism by which
caspase-8 activation at the inflammasome can cause secondary
pyroptosis, but further research will be required to address this
and other possible mechanisms.
EXPERIMENTAL PROCEDURES
Mice
Nlrp3/, B6.129-Casp1/11/ (Kuida et al., 1995), B6.C-Tg(CMV-cre)1Cgn/J,
GSDMD/, B6-Casp1mlt/mlt, B6.129-Casp1mlt/mlt, and B6-Casp1/ mice
were housed under SPF or SOPF conditions at the Zentrum f€ur Pra¨klinische
Forschung (Munich, Germany), Charles River Laboratories (Italy), or the
Biozentrum, University of Basel (Switzerland), in accordance with local and
European guidelines, as well as Federation for Laboratory Animal Science
Associations (FELASA) recommendations. Casp1mlt mice were generated by
conventional gene targeting in both C57BL/6 and 129 genetic backgrounds,
and Casp1- and GSDMD-deficient mice were generated by CRISPR/Cas9
technology, as described in detail in the Supplemental Information.
Reagents
All tissueculture reagentswere from Invitrogen, unless indicatedotherwise. Toll-
like receptor (TLR) ligands were from InvivoGen. Raptinal was from AdipoGen
Life Sciences. All other chemicals and reagents were from Sigma, unless indi-
cated otherwise. Sources and identifiers of the antibodies used can be found
in the Supplemental Information. Salmonella enterica subspecies I serovar
Typhimurium X3625 (DaroA) (Salmonella enterica serovar Typhimurium) was a
gift from Ba¨rbel Stecher, Munich. Kits used for cloning were from Promega.
Inflammasome Activation and Analysis
BMDCs were generated and stimulated as previously described (Groß et al.,
2016; Schneider et al., 2013). Cells were primed with 50 ng/mL of ultrapure
LPS for 3 hr, and inhibitors were added 30 min before stimulation with inflam-
masome activators at optimal concentrations, as outlined in the Supplemental
Information. Stimulation with nigericin was performed with a final concentra-
tion of 5–10 mM and for a duration of 45–60 min. ELISA, immunoblot analysis,
and other measurements were performed as described in detail in the Supple-
mental Information.
Animal Infection
Infection of mice with wild-type F. novicida strain U112 was performed at the
Biozentrum, University of Basel. All animal experiments were approved (license
2535-26742, Kantonales Veterina¨ramt Basel-Stadt) and were performedCell Reports 21, 3846–3859, December 26, 2017 3857
according to local guidelines (Tierschutz-Verordnung, Basel-Stadt) and the
Swiss animal protection law (Tierschutz-Gesetz). Bacteria were cultured over-
night in brain heart infusion (BHI) medium (supplemented with 100 mg/mL ampi-
cillin [AppliChem] and 0.2% L-cysteine). Bacteria were harvested by centrifuga-
tion and washed once with 13 Dulbecco’s Phosphate-Buffered Saline (DPBS).
Mice were infected subcutaneously with 5 3 103 CFU in 50 mL 13 DPBS. In-
fected mice had access to food and water ad libitum. Mice were sacrificed
48 hr after infection, and spleen and liver were harvested. Colony-forming units
(CFUs) were determined from spleen and liver homogenates plated in serial
dilutions on Mueller-Hinton agar plates supplemented with 0.1% D-glucose
(Millipore), 0.1% fetal calf serum (FCS) (BioConcept), 100 mg/mL ampicillin
(AppliChem), and 0.1% L-cysteine. Statistical analysis was performed using
GraphPad Prism 6.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at https://doi.org/10.
1016/j.celrep.2017.12.018.
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